Implications for KRAS status and EGFR-targeted therapies in metastatic CRC (original) (raw)

• Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Eng. J. Med. 358, 1160–1174 (2008).
  Article CAS Google Scholar
• Shepard, H. M., Brdlik, C. M. & Schreiber, H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J. Clin. Invest. 118, 3574–3581 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Normanno, N., Bianco, C., De Luca, A., Maiello, M. R. & Salomon, D. S. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10, 1–21 (2003).
  Article CAS PubMed Google Scholar
• Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459–465 (2003).
  Article CAS PubMed Google Scholar
• Koera, K. et al. K-ras is essential for the development of the mouse embryo. Oncogene 15, 1151–1159 (1997).
  Article CAS PubMed Google Scholar
• Johnson, L. et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468–2481 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600–608 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Schafer, W. R. et al. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science 249, 1133–1139 (1990).
  Article CAS PubMed Google Scholar
• Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295–308 (2007).
  Article CAS PubMed Google Scholar
• Rosen, N. Molecular biology of gastrointestinal cancers. In Cancer—Principles and Practice of Oncology 5th edn (Eds DeVita, V. T. J., Hellman, S. & Rosenberg, S. A.) 971–979 (Lippincott Williams & Wilkins, 1997).
  Google Scholar
• Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
  Article CAS PubMed Google Scholar
• Bos, J. L. et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293–297 (1987).
  Article CAS PubMed Google Scholar
• Samowitz, W. S. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063–6069 (2005).
  Article CAS PubMed Google Scholar
• Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90–96 (2009).
  Article PubMed Google Scholar
• Takayama, T. et al. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121, 599–611 (2001).
  Article CAS PubMed Google Scholar
• Pretlow, T. P. & Pretlow, T. G. Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer? Biochim. Biophys. Acta 1756, 83–96 (2005).
  CAS PubMed Google Scholar
• Santini, D. et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13, 1270–1275 (2008).
  Article CAS PubMed Google Scholar
• Artale, S. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217–4219 (2008).
  Article PubMed Google Scholar
• Forbes, S. et al. Cosmic 2005. Br. J. Cancer 94, 318–322 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  CAS PubMed Google Scholar
• Andreyev, H. J. et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 85, 692–696 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643–2648 (2007).
  Article CAS PubMed Google Scholar
• Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumimab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705–5712 (2008).
  Article CAS PubMed Google Scholar
• Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R. & Clarke, P. A. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J. Natl Cancer Inst. 90, 675–684 (1998).
  Article CAS PubMed Google Scholar
• Samowitz, W. S. et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev. 9, 1193–1197 (2000).
  CAS PubMed Google Scholar
• Westra, J. L. et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol. 23, 5635–5643 (2005).
  Article CAS PubMed Google Scholar
• Barault, L. et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer 122, 2255–2259 (2008).
  Article CAS PubMed Google Scholar
• Belly, R. T. et al. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. Clin. Colorectal Cancer 1, 110–116 (2001).
  Article CAS PubMed Google Scholar
• Moroni, M. et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279–286 (2005).
  Article CAS PubMed Google Scholar
• Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995 (2006).
  Article PubMed Google Scholar
• Frattini, M. et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br. J. Cancer 9, 1139–1145 (2007).
  Article Google Scholar
• Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br. J. Cancer 96, 1166–1169 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Khambata-Ford, S. et al. Expression of epregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230–3237 (2007).
  Article CAS PubMed Google Scholar
• De Roock, W. et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508–515 (2008).
  Article CAS PubMed Google Scholar
• Lièvre, A. et al. KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374–379 (2008).
  Article PubMed Google Scholar
• Bibeau, F. et al. Impact of FcγRIIa–FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27, 1122–1129 (2009).
  Article CAS PubMed Google Scholar
• Amado, R. G. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 1626–1634 (2008).
  Article CAS PubMed Google Scholar
• Karapetis, C. S. et al. KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008).
  Article CAS PubMed Google Scholar
• Cervantes, A. et al. Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. ASCO Meeting Abstracts 26, 4129 (2008).
  Google Scholar
• Folprecht, G. et al. Cetuximab plus FOLFOX or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: A randomized multicenter study (CELIM study) [abstract]. Gastrointestinal Cancer Symposium 2009: 296 (2009).
• Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2008).
  Article PubMed Google Scholar
• Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408–1417 (2009).
  Article CAS PubMed Google Scholar
• Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene muations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091–2096 (2009).
  Article PubMed Google Scholar
• van Krieken, J. H. et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 454, 233–235 (2008).
  Article Google Scholar
• Jimeno, A., Messersmith, W. A., Hirsch, F. R., Franklin, W. A. & Eckhardt, S. G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 27, 1130–1136 (2009).
  Article CAS PubMed Google Scholar
• Ogino, S. et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J. Mol. Diagn. 3, 413–421 (2005).
  Article Google Scholar
• Juan, T. et al. A comparability study of 4 commercial KRAS tests [abstract]. AACR Meeting Abstracts 2008: 1811 (2008).
• Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 10, 962–972 (2008).
  Article Google Scholar
• Cappuzzo, F. et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19, 717–723 (2008).
  Article CAS PubMed Google Scholar
• Personeni, N. et al. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin. Cancer Res. 14, 5869–5876 (2008).
  Article CAS PubMed Google Scholar
• De Roock, W., Lambrechts, D. & Tejpar, S. K-ras mutations and cetuximab in colorectal cancer. N. Engl. J. Med. 360, 834 (2009).
  CAS PubMed Google Scholar
• Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84–90 (2009).
  Article CAS PubMed Google Scholar
• Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851–1857 (2009).
  Article CAS PubMed Google Scholar
• Loupakis, F. et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment [abstract]. ASCO Meeting Abstracts 26, 4003 (2008).
  Google Scholar
• Morgillo, F., Bareschino, M. A., Bianco, R., Tortora, G. & Ciardiello, F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 75, 788–799 (2007).
  Article CAS PubMed Google Scholar
• Jorissen, R. N. et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell Res. 284, 31–53 (2003).
  Article CAS PubMed Google Scholar
• Yordy, J. S. & Muise-Helmericks, R. C. Signal transduction and the Ets family of transcription factors. Oncogene 19, 6503–6513 (2000).
  Article CAS PubMed Google Scholar
• Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417, 867–871 (2002).
  Article CAS PubMed Google Scholar
• Wolthuis, R. M. & Bos, J. L. Ras caught in another affair: the exchange factors for Ral. Curr. Opin. Genet. Dev. 9, 112–117 (1999).
  Article CAS PubMed Google Scholar
• Kelley, G. G., Reks, S. E., Ondrako, J. M. & Smrcka, A. V. Phospholipase C(epsilon): a novel Ras effector. EMBO J. 20, 743–754 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Song, C. et al. Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras. J. Biol. Chem. 276, 2752–2757 (2001).
  Article CAS PubMed Google Scholar